242 related articles for article (PubMed ID: 11196163)
1. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant.
Kass E; Panicali DL; Mazzara G; Schlom J; Greiner JW
Cancer Res; 2001 Jan; 61(1):206-14. PubMed ID: 11196163
[TBL] [Abstract][Full Text] [Related]
2. Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity.
Hodge JW; McLaughlin JP; Abrams SI; Shupert WL; Schlom J; Kantor JA
Cancer Res; 1995 Aug; 55(16):3598-603. PubMed ID: 7543017
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate.
Kantor J; Irvine K; Abrams S; Snoy P; Olsen R; Greiner J; Kaufman H; Eggensperger D; Schlom J
Cancer Res; 1992 Dec; 52(24):6917-25. PubMed ID: 1458480
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen.
Samanci A; Yi Q; Fagerberg J; Strigård K; Smith G; Rudén U; Wahren B; Mellstedt H
Cancer Immunol Immunother; 1998 Nov; 47(3):131-42. PubMed ID: 9829838
[TBL] [Abstract][Full Text] [Related]
5. The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines.
Arlen P; Tsang KY; Marshall JL; Chen A; Steinberg SM; Poole D; Hand PH; Schlom J; Hamilton JM
Cancer Immunol Immunother; 2000 Dec; 49(10):517-29. PubMed ID: 11129322
[TBL] [Abstract][Full Text] [Related]
6. Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells.
Morrissey PJ; Bressler L; Park LS; Alpert A; Gillis S
J Immunol; 1987 Aug; 139(4):1113-9. PubMed ID: 3038997
[TBL] [Abstract][Full Text] [Related]
7. Secretion of colony-stimulating factors by T cell clones. Role in adoptive protection against Listeria monocytogenes.
Magee DM; Wing EJ
J Immunol; 1989 Oct; 143(7):2336-41. PubMed ID: 2674280
[TBL] [Abstract][Full Text] [Related]
8. Production of colony-stimulating factor by tumor cells and the factor-mediated induction of suppressor cells.
Tsuchiya Y; Igarashi M; Suzuki R; Kumagai K
J Immunol; 1988 Jul; 141(2):699-708. PubMed ID: 2968407
[TBL] [Abstract][Full Text] [Related]
9. A carcinoembryonic antigen polynucleotide vaccine for human clinical use.
Conry RM; LoBuglio AF; Loechel F; Moore SE; Sumerel LA; Barlow DL; Pike J; Curiel DT
Cancer Gene Ther; 1995 Mar; 2(1):33-8. PubMed ID: 7621253
[TBL] [Abstract][Full Text] [Related]
10. Immune response to a carcinoembryonic antigen polynucleotide vaccine.
Conry RM; LoBuglio AF; Kantor J; Schlom J; Loechel F; Moore SE; Sumerel LA; Barlow DL; Abrams S; Curiel DT
Cancer Res; 1994 Mar; 54(5):1164-8. PubMed ID: 8118800
[TBL] [Abstract][Full Text] [Related]
11. T-cell responses to orally administered antigens. Study of the kinetics of lymphokine production after single and multiple feeding.
Hoyne GF; Thomas WR
Immunology; 1995 Feb; 84(2):304-9. PubMed ID: 7751007
[TBL] [Abstract][Full Text] [Related]
12. A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity.
Conry RM; LoBuglio AF; Loechel F; Moore SE; Sumerel LA; Barlow DL; Curiel DT
Gene Ther; 1995 Jan; 2(1):59-65. PubMed ID: 7712333
[TBL] [Abstract][Full Text] [Related]
13. The antitumor and immunoadjuvant effects of IFN-alpha in combination with recombinant poxvirus vaccines.
Hance KW; Rogers CJ; Zaharoff DA; Canter D; Schlom J; Greiner JW
Clin Cancer Res; 2009 Apr; 15(7):2387-96. PubMed ID: 19276249
[TBL] [Abstract][Full Text] [Related]
14. Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor.
Chen TT; Tao MH; Levy R
J Immunol; 1994 Nov; 153(10):4775-87. PubMed ID: 7525715
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine.
Kantor J; Irvine K; Abrams S; Kaufman H; DiPietro J; Schlom J
J Natl Cancer Inst; 1992 Jul; 84(14):1084-91. PubMed ID: 1619682
[TBL] [Abstract][Full Text] [Related]
16. Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen.
Hodge JW; Higgins J; Schlom J
Vaccine; 2009 Jul; 27(33):4475-82. PubMed ID: 19450631
[TBL] [Abstract][Full Text] [Related]
17. GM-CSF produced by recombinant vaccinia virus or in GM-CSF transgenic mice has no effect in vivo on murine cutaneous leishmaniasis.
Corcoran LM; Metcalf D; Edwards SJ; Handman E
J Parasitol; 1988 Oct; 74(5):763-7. PubMed ID: 3047351
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms contributing to the sex difference in levels of granulocyte-macrophage colony-stimulating factor in the urine of GM-CSF transgenic mice.
Metcalf D
Exp Hematol; 1988 Oct; 16(9):794-800. PubMed ID: 3049131
[TBL] [Abstract][Full Text] [Related]
19. Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effects.
Osada T; Berglund P; Morse MA; Hubby B; Lewis W; Niedzwiecki D; Yang XY; Hobeika A; Burnett B; Devi GR; Clay TM; Smith J; Kim Lyerly H
Cancer Immunol Immunother; 2012 Nov; 61(11):1941-51. PubMed ID: 22488274
[TBL] [Abstract][Full Text] [Related]
20. Induction of autoantibody responses to GM-CSF by hyperimmunization with an Id-GM-CSF fusion protein.
Chen TT; Levy R
J Immunol; 1995 Apr; 154(7):3105-17. PubMed ID: 7897201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
